Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-04-15

AUTHORS

P. M. Clarke, A. M. Gray, A. Briggs, R. J. Stevens, D. R. Matthews, R. R. Holman, on behalf of the UK Prospective Diabetes Study (UKPDS)

ABSTRACT

Aims/hypothesisThis study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.MethodsWe conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.ResultsThe incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was £6,028, and for blood pressure control was £369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.Conclusions/interpretationEach of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions. More... »

PAGES

868-877

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3

DOI

http://dx.doi.org/10.1007/s00125-005-1717-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003605836

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15834550


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Complications", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415193.b", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK", 
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "P. M.", 
        "id": "sg:person.0734456474.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "A. M.", 
        "id": "sg:person.01307325071.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Briggs", 
        "givenName": "A.", 
        "id": "sg:person.01142063040.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142063040.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stevens", 
        "givenName": "R. J.", 
        "id": "sg:person.01052527755.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matthews", 
        "givenName": "D. R.", 
        "id": "sg:person.01216556762.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216556762.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holman", 
        "givenName": "R. R.", 
        "id": "sg:person.01017043005.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "on behalf of the UK Prospective Diabetes Study (UKPDS)", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250051617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001128875", 
          "https://doi.org/10.1007/s001250051617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022043816", 
          "https://doi.org/10.1007/bf00400195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4612-1304-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007161826", 
          "https://doi.org/10.1007/978-1-4612-1304-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-04-15", 
    "datePublishedReg": "2005-04-15", 
    "description": "Aims/hypothesisThis study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.MethodsWe conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.ResultsThe incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was \u00a36,028, and for blood pressure control was \u00a3369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.Conclusions/interpretationEach of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00125-005-1717-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6719947", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "48"
      }
    ], 
    "keywords": [
      "intensive blood glucose control", 
      "tight blood pressure control", 
      "blood pressure control", 
      "blood glucose control", 
      "type 2 diabetes", 
      "quality-adjusted life years", 
      "UK Prospective Diabetes Study", 
      "glucose control", 
      "cost-utility analysis", 
      "pressure control", 
      "life years", 
      "metformin therapy", 
      "healthcare resources", 
      "type 2 diabetic patients", 
      "hospital-based clinics", 
      "patient-level data", 
      "intensive blood glucose", 
      "Prospective Diabetes Study", 
      "UKPDS Outcomes Model", 
      "care of patients", 
      "quality-adjusted life expectancy", 
      "overweight patients", 
      "hypertensive patients", 
      "diabetic patients", 
      "Diabetes Study", 
      "blood glucose", 
      "patients", 
      "diabetes", 
      "trial effects", 
      "incremental cost", 
      "effectiveness ratio", 
      "life expectancy", 
      "therapy", 
      "outcome model", 
      "years", 
      "hypertension", 
      "control", 
      "metformin", 
      "clinic", 
      "MethodsWe", 
      "insulin", 
      "trials", 
      "net cost", 
      "care", 
      "intervention", 
      "study", 
      "glucose", 
      "expectancy", 
      "rationale", 
      "Northern Ireland", 
      "levels", 
      "effect", 
      "analysis", 
      "data", 
      "effectiveness", 
      "ratio", 
      "results", 
      "England", 
      "Scotland", 
      "cost", 
      "part", 
      "Ireland", 
      "uses", 
      "economic rationale", 
      "economic efficiency", 
      "different policies", 
      "model", 
      "policy", 
      "low cost", 
      "terms", 
      "resources", 
      "corresponds", 
      "lifetime", 
      "efficiency", 
      "Aims/hypothesisThis study", 
      "hypothesisThis study", 
      "sulphonylurea/insulin", 
      "Conclusions/interpretationEach", 
      "interpretationEach", 
      "type 2 diabetes corresponds", 
      "diabetes corresponds"
    ], 
    "name": "Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)", 
    "pagination": "868-877", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003605836"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00125-005-1717-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15834550"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00125-005-1717-3", 
      "https://app.dimensions.ai/details/publication/pub.1003605836"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00125-005-1717-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      22 PREDICATES      125 URIs      113 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00125-005-1717-3 schema:about N242300a817e64d10ab7a02849c7d7989
2 N271064e89b564470954a5acb7007a34e
3 N4a528693099a475194bd1871012465e8
4 N5cb80ee49ae64cc0a1f310333a4c38a5
5 N60993e5b616d493b82c3fc439ab972e0
6 N61b92bf17e2b4cee8a45a81945d9a1e9
7 N6d15e12e16ea4fd09e9e77eb7c4666a8
8 N7b1a8400f16c4cda857356b4cb0d1b70
9 N8021bc8acac448e092a54f5b010c287e
10 Na9c216ccd283415eb7568c201a260d81
11 Nc3f145b42d4844b1aa9883f32511d878
12 Ncb1cdab12e45440a9c62994cdf428141
13 Nd9e07427751540e6af5e1a2fc87424ca
14 Nec60e87b319e4063a77fbfba91a467e2
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nb13329b76a1f4b8c97fcc1a366f00c97
18 schema:citation sg:pub.10.1007/978-1-4612-1304-8
19 sg:pub.10.1007/bf00400195
20 sg:pub.10.1007/s00125-004-1527-z
21 sg:pub.10.1007/s001250051617
22 schema:datePublished 2005-04-15
23 schema:datePublishedReg 2005-04-15
24 schema:description Aims/hypothesisThis study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.MethodsWe conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.ResultsThe incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was £6,028, and for blood pressure control was £369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.Conclusions/interpretationEach of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N0382362b8f9a402882d8878a5c41575a
29 N56a4479d3b1c42798a8c2e6dd4ee59fb
30 sg:journal.1001482
31 schema:keywords Aims/hypothesisThis study
32 Conclusions/interpretationEach
33 Diabetes Study
34 England
35 Ireland
36 MethodsWe
37 Northern Ireland
38 Prospective Diabetes Study
39 Scotland
40 UK Prospective Diabetes Study
41 UKPDS Outcomes Model
42 analysis
43 blood glucose
44 blood glucose control
45 blood pressure control
46 care
47 care of patients
48 clinic
49 control
50 corresponds
51 cost
52 cost-utility analysis
53 data
54 diabetes
55 diabetes corresponds
56 diabetic patients
57 different policies
58 economic efficiency
59 economic rationale
60 effect
61 effectiveness
62 effectiveness ratio
63 efficiency
64 expectancy
65 glucose
66 glucose control
67 healthcare resources
68 hospital-based clinics
69 hypertension
70 hypertensive patients
71 hypothesisThis study
72 incremental cost
73 insulin
74 intensive blood glucose
75 intensive blood glucose control
76 interpretationEach
77 intervention
78 levels
79 life expectancy
80 life years
81 lifetime
82 low cost
83 metformin
84 metformin therapy
85 model
86 net cost
87 outcome model
88 overweight patients
89 part
90 patient-level data
91 patients
92 policy
93 pressure control
94 quality-adjusted life expectancy
95 quality-adjusted life years
96 ratio
97 rationale
98 resources
99 results
100 study
101 sulphonylurea/insulin
102 terms
103 therapy
104 tight blood pressure control
105 trial effects
106 trials
107 type 2 diabetes
108 type 2 diabetes corresponds
109 type 2 diabetic patients
110 uses
111 years
112 schema:name Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
113 schema:pagination 868-877
114 schema:productId N092d0dab06ca402ea3ccf0681fdaccd6
115 N0b3001dc34a94d54bc5772beec21fdd1
116 N743c91f8f79e43cd83a4faf68b8ae2f2
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003605836
118 https://doi.org/10.1007/s00125-005-1717-3
119 schema:sdDatePublished 2021-11-01T18:08
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N88786ad557794353a85cfc80dbd91d43
122 schema:url https://doi.org/10.1007/s00125-005-1717-3
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N02da510196904f42b3a33166204f6325 schema:familyName on behalf of the UK Prospective Diabetes Study (UKPDS)
127 rdf:type schema:Person
128 N0382362b8f9a402882d8878a5c41575a schema:issueNumber 5
129 rdf:type schema:PublicationIssue
130 N092d0dab06ca402ea3ccf0681fdaccd6 schema:name dimensions_id
131 schema:value pub.1003605836
132 rdf:type schema:PropertyValue
133 N0b3001dc34a94d54bc5772beec21fdd1 schema:name doi
134 schema:value 10.1007/s00125-005-1717-3
135 rdf:type schema:PropertyValue
136 N242300a817e64d10ab7a02849c7d7989 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Blood Glucose
138 rdf:type schema:DefinedTerm
139 N271064e89b564470954a5acb7007a34e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Hypertension
141 rdf:type schema:DefinedTerm
142 N32af0dd625e14455a95e862bf1e852bf rdf:first N02da510196904f42b3a33166204f6325
143 rdf:rest rdf:nil
144 N3ea76326ec4d4039af5f7cbf698f21f3 rdf:first sg:person.01142063040.42
145 rdf:rest N6d1d7da4b0a046bca726ebbc5db9e846
146 N43ca9092e0c54fa8af7419f8adcba74c rdf:first sg:person.01017043005.08
147 rdf:rest N32af0dd625e14455a95e862bf1e852bf
148 N4a528693099a475194bd1871012465e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name United Kingdom
150 rdf:type schema:DefinedTerm
151 N4d05ead0ee34484697bb181140fc70d3 rdf:first sg:person.01307325071.02
152 rdf:rest N3ea76326ec4d4039af5f7cbf698f21f3
153 N56a4479d3b1c42798a8c2e6dd4ee59fb schema:volumeNumber 48
154 rdf:type schema:PublicationVolume
155 N5cb80ee49ae64cc0a1f310333a4c38a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Diabetes Mellitus, Type 2
157 rdf:type schema:DefinedTerm
158 N60993e5b616d493b82c3fc439ab972e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Adult
160 rdf:type schema:DefinedTerm
161 N61b92bf17e2b4cee8a45a81945d9a1e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Cost-Benefit Analysis
163 rdf:type schema:DefinedTerm
164 N6d15e12e16ea4fd09e9e77eb7c4666a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Diabetes Complications
166 rdf:type schema:DefinedTerm
167 N6d1d7da4b0a046bca726ebbc5db9e846 rdf:first sg:person.01052527755.23
168 rdf:rest N886319b7533b40d6bbd2c4f9c3969491
169 N743c91f8f79e43cd83a4faf68b8ae2f2 schema:name pubmed_id
170 schema:value 15834550
171 rdf:type schema:PropertyValue
172 N7b1a8400f16c4cda857356b4cb0d1b70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Antihypertensive Agents
174 rdf:type schema:DefinedTerm
175 N8021bc8acac448e092a54f5b010c287e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Hypoglycemic Agents
177 rdf:type schema:DefinedTerm
178 N886319b7533b40d6bbd2c4f9c3969491 rdf:first sg:person.01216556762.76
179 rdf:rest N43ca9092e0c54fa8af7419f8adcba74c
180 N88786ad557794353a85cfc80dbd91d43 schema:name Springer Nature - SN SciGraph project
181 rdf:type schema:Organization
182 Na9c216ccd283415eb7568c201a260d81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Aged
184 rdf:type schema:DefinedTerm
185 Nb13329b76a1f4b8c97fcc1a366f00c97 rdf:first sg:person.0734456474.38
186 rdf:rest N4d05ead0ee34484697bb181140fc70d3
187 Nc3f145b42d4844b1aa9883f32511d878 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Middle Aged
189 rdf:type schema:DefinedTerm
190 Ncb1cdab12e45440a9c62994cdf428141 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Humans
192 rdf:type schema:DefinedTerm
193 Nd9e07427751540e6af5e1a2fc87424ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Costs and Cost Analysis
195 rdf:type schema:DefinedTerm
196 Nec60e87b319e4063a77fbfba91a467e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Blood Pressure
198 rdf:type schema:DefinedTerm
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
203 schema:name Clinical Sciences
204 rdf:type schema:DefinedTerm
205 sg:grant.6719947 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-005-1717-3
206 rdf:type schema:MonetaryGrant
207 sg:journal.1001482 schema:issn 0012-186X
208 1432-0428
209 schema:name Diabetologia
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01017043005.08 schema:affiliation grid-institutes:grid.4991.5
213 schema:familyName Holman
214 schema:givenName R. R.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08
216 rdf:type schema:Person
217 sg:person.01052527755.23 schema:affiliation grid-institutes:grid.4991.5
218 schema:familyName Stevens
219 schema:givenName R. J.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23
221 rdf:type schema:Person
222 sg:person.01142063040.42 schema:affiliation grid-institutes:grid.4991.5
223 schema:familyName Briggs
224 schema:givenName A.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142063040.42
226 rdf:type schema:Person
227 sg:person.01216556762.76 schema:affiliation grid-institutes:grid.4991.5
228 schema:familyName Matthews
229 schema:givenName D. R.
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216556762.76
231 rdf:type schema:Person
232 sg:person.01307325071.02 schema:affiliation grid-institutes:grid.4991.5
233 schema:familyName Gray
234 schema:givenName A. M.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02
236 rdf:type schema:Person
237 sg:person.0734456474.38 schema:affiliation grid-institutes:grid.415193.b
238 schema:familyName Clarke
239 schema:givenName P. M.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38
241 rdf:type schema:Person
242 sg:pub.10.1007/978-1-4612-1304-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007161826
243 https://doi.org/10.1007/978-1-4612-1304-8
244 rdf:type schema:CreativeWork
245 sg:pub.10.1007/bf00400195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022043816
246 https://doi.org/10.1007/bf00400195
247 rdf:type schema:CreativeWork
248 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
249 https://doi.org/10.1007/s00125-004-1527-z
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s001250051617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001128875
252 https://doi.org/10.1007/s001250051617
253 rdf:type schema:CreativeWork
254 grid-institutes:grid.415193.b schema:alternateName Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia
255 schema:name Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia
256 Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
257 Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK
258 rdf:type schema:Organization
259 grid-institutes:grid.4991.5 schema:alternateName Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK
260 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
261 schema:name Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
262 Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK
263 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...